Drugs & Aging

, Volume 35, Issue 4, pp 303–319 | Cite as

Impact of Deprescribing Interventions in Older Hospitalised Patients on Prescribing and Clinical Outcomes: A Systematic Review of Randomised Trials

  • Janani Thillainadesan
  • Danijela Gnjidic
  • Sarah Green
  • Sarah N. Hilmer
Systematic Review

Abstract

Background

Polypharmacy and potentially inappropriate medications (PIMs) are prevalent in older adults in hospital, and are associated with negative outcomes including adverse drug reactions, falls, confusion, hospitalisation and death. Deprescribing may reduce inappropriate polypharmacy and use of inappropriate medications.

Objective

The aim of this systematic review was to investigate the efficacy of deprescribing interventions in older inpatients to reduce PIMs and impact on clinical outcomes.

Methods

Ovid MEDLINE, Embase, Informit, International Pharmaceutical Abstracts, Scopus, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL) and CINAHL were searched for randomised controlled trials (RCTs) from 1996 to April 2017. RCTs reporting on deprescribing interventions to reduce PIMs in older hospitalised adults were eligible. Data were extracted, and study quality assessed. The primary outcome was reduction in PIMs. Where available, clinically relevant outcomes were assessed.

Results

Nine RCTs (n = 2522 subjects) met the inclusion criteria. Deprescribing interventions were either pharmacist-led (n = 4), physician-led (n = 4) or multidisciplinary team-led (n = 1). Seven of the nine studies reported a statistically significant reduction in PIMs in the intervention group. There was no change in one study where there were zero PIMs on admission and discharge, and in the other study a reduction in PIMs that was not statistically significant was observed. There was significant heterogeneity in outcome measures and reporting. Few studies reported on the impact of deprescribing interventions on clinical outcomes. Reported clinical outcomes included drug-related problems (n = 3), quality of life (n = 2), mortality (n = 3), hospital readmissions (n = 4), falls (n = 3) and functional status (n = 2). Most studies reported a benefit in the intervention group that was not statistically significant. No notable harm was observed in the intervention group. There was a high risk of bias in the included studies.

Conclusions

The evidence available suggests that deprescribing interventions in hospital are feasible, generally effective at reducing PIMs and safe. However, the current evidence is limited, of low quality and the impact on clinical outcomes is unclear.

Notes

Compliance with Ethical Standards

Funding

No funding was used in the preparation of this manuscript. However, the findings will inform NSW Health Translational Research Grant 274, ‘Reducing Inappropriate Polypharmacy in Older Inpatients’, chief investigator Sarah Hilmer.

Conflict of interest

Janani Thillainadesan, Danijela Gnjidic, Sarah Green and Sarah Hilmer declare that they have no conflicts of interest relevant to the content of this review.

Supplementary material

40266_2018_536_MOESM1_ESM.docx (54 kb)
Supplementary material 1 (DOCX 53 kb)

References

  1. 1.
    Australian Institute of Health and Welfare. Australia’s hospitals 2014–2015 at a glance. Health Services Series, No. 70. Catalogue No. HSE 175 Canberra, Australia; 2016.Google Scholar
  2. 2.
    Beard JR, Officer A, de Carvalho IA, Sadana R, Pot AM, Michel J-P, et al. The World report on ageing and health: a policy framework for healthy ageing. Lancet. 2016;387(10033):2145–54.CrossRefPubMedGoogle Scholar
  3. 3.
    Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M, et al. Global multimorbidity patterns: a cross-sectional, population-based, multi-country study. J Gerontol A Biol Sci Med Sci. 2016;71(2):205–14.CrossRefPubMedGoogle Scholar
  4. 4.
    Held FP, Blyth F, Gnjidic D, Hirani V, Naganathan V, Waite LM, et al. Association rules analysis of comorbidity and multimorbidity: the concord health and aging in men project. J Gerontol A Biol Sci Med Sci. 2016;71(5):625–31.  https://doi.org/10.1093/gerona/glv181.CrossRefPubMedGoogle Scholar
  5. 5.
    Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10(4):430–9.CrossRefPubMedGoogle Scholar
  6. 6.
    American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–46.  https://doi.org/10.1111/jgs.13702.CrossRefGoogle Scholar
  7. 7.
    O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.  https://doi.org/10.1093/ageing/afu145.CrossRefPubMedGoogle Scholar
  8. 8.
    Ni Chroinin D, Neto HM, Xiao D, Sandhu A, Brazel C, Farnham N, et al. Potentially inappropriate medications (PIMs) in older hospital in-patients: prevalence, contribution to hospital admission and documentation of rationale for continuation. Australas J Ageing. 2016;35(4):262–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Beer C, Hyde Z, Almeida OP, Norman P, Hankey GJ, Yeap BB, et al. Quality use of medicines and health outcomes among a cohort of community dwelling older men: an observational study. Br J Clin Pharmacol. 2011;71(4):592–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012;65(9):989–95.CrossRefPubMedGoogle Scholar
  11. 11.
    Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Expert Opin Drug Saf. 2014;13(1):57–65.CrossRefPubMedGoogle Scholar
  12. 12.
    Wallace E, McDowell R, Bennett K, Fahey T, Smith SM. Impact of potentially inappropriate prescribing on adverse drug events, health related quality of life and emergency hospital attendance in older people attending general practice: a prospective cohort study. J Gerontol A Biol Sci Med Sci. 2017;72(2):271–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Woodward MC. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res. 2003;33(4):323–8.CrossRefGoogle Scholar
  14. 14.
    Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’ with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–68.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gnjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28(2):237–53.CrossRefPubMedGoogle Scholar
  16. 16.
    Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583–623.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older. Drugs Aging. 2008;25(12):1021–31.CrossRefPubMedGoogle Scholar
  18. 18.
    Boghossian TA, Rashid FJ, Welch V, Rojas-Fernandez C, Moayyedi P, Pottie K, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2015;16(3):CD011969.  https://doi.org/10.1002/14651858.cd011969.pub2.Google Scholar
  19. 19.
    Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter A, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;28(3):CD007726.  https://doi.org/10.1002/14651858.cd007726.pub2.Google Scholar
  20. 20.
    Johansson T, Abuzahra ME, Keller S, Mann E, Faller B, Sommerauer C, et al. Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(2):532–48.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Qi K, Reeve E, Hilmer SN, Pearson S-A, Matthews S, Gnjidic D. Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm. 2015;37(5):949–57.  https://doi.org/10.1007/s11096-015-0147-7.CrossRefPubMedGoogle Scholar
  22. 22.
    Chan B, Reeve E, Matthews S, Carroll PR, Long JC, Held F, et al. Medicine information exchange networks among healthcare professionals and prescribing in geriatric medicine wards. Br J Clin Pharmacol. 2017;83(6):1185–96.  https://doi.org/10.1111/bcp.13222.CrossRefPubMedGoogle Scholar
  23. 23.
    Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2016;2:Cd008986.  https://doi.org/10.1002/14651858.cd008986.pub3.PubMedGoogle Scholar
  24. 24.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167(8):781–7.  https://doi.org/10.1001/archinte.167.8.781.CrossRefPubMedGoogle Scholar
  26. 26.
    Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45(10):1045–51.CrossRefPubMedGoogle Scholar
  27. 27.
    O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44(2):213–8.  https://doi.org/10.1093/ageing/afu145.CrossRefPubMedGoogle Scholar
  28. 28.
    Higgins JPT, Altman DG, Sterne JAC. Chapter 8: assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. (updated March 2011). ed: The Cochrane Collaboration, 2011.Google Scholar
  29. 29.
    Bladh L, Ottosson E, Karlsson J, Klintberg L, Wallerstedt SM. Effects of a clinical pharmacist service on health-related quality of life and prescribing of drugs: a randomised controlled trial. BMJ Qual Saf. 2011;20(9):738–46.  https://doi.org/10.1136/bmjqs.2009.039693.CrossRefPubMedGoogle Scholar
  30. 30.
    Dalleur O, Boland B, Losseau C, Henrard S, Wouters D, Speybroeck N, et al. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. Drugs Aging. 2014;31(4):291–8.  https://doi.org/10.1007/s40266-014-0157-5.CrossRefPubMedGoogle Scholar
  31. 31.
    Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011;89(6):845–54.  https://doi.org/10.1038/clpt.2011.44.CrossRefPubMedGoogle Scholar
  32. 32.
    Gillespie U, Alassaad A, Hammarlund-Udenaes M, Mörlin C, Henrohn D, Bertilsson M, et al. Effects of pharmacists’ interventions on appropriateness of prescribing and evaluation of the instruments’(MAI, STOPP and STARTs’) ability to predict hospitalization–analyses from a randomized controlled trial. PLoS One. 2013;8(5):e62401.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Michalek C, Wehling M, Schlitzer J, Frohnhofen H. Effects of ‘Fit fOR The Aged’ (FORTA) on pharmacotherapy and clinical endpoints-a pilot randomized controlled study. Eur J Clin Pharmacol. 2014;70(10):1261–7.  https://doi.org/10.1007/s00228-014-1731-9.CrossRefPubMedGoogle Scholar
  34. 34.
    Schmader KE, Hanlon JT, Pieper CF, Sloane R, Ruby CM, Twersky J, et al. Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly. Am J Med. 2004;116(6):394–401.  https://doi.org/10.1016/j.amjmed.2003.10.031.CrossRefPubMedGoogle Scholar
  35. 35.
    Spinewine A, Swine C, Dhillon S, Lambert P, Nachega JB, Wilmotte L, et al. Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial. J Am Geriatr Soc. 2007;55(5):658–65.  https://doi.org/10.1111/j.1532-5415.2007.01132.x.CrossRefPubMedGoogle Scholar
  36. 36.
    Van der Linden L, Decoutere L, Walgraeve K, Milisen K, Flamaing J, Spriet I, et al. Combined use of the rationalization of home medication by an adjusted STOPP in older patients (RASP) list and a pharmacist-led medication review in very old inpatients: impact on quality of prescribing and clinical outcome. Drugs Aging. 2017;34(2):123–33.  https://doi.org/10.1007/s40266-016-0424-8.CrossRefPubMedGoogle Scholar
  37. 37.
    Wehling M, Burkhardt H, Kuhn-Thiel A, Pazan F, Throm C, Weiss C, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016;45(2):262–7.  https://doi.org/10.1093/ageing/afv200.CrossRefPubMedGoogle Scholar
  38. 38.
    Patterson SM, Cadogan CA, Kerse N, Cardwell CR, Bradley MC, Ryan C, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014.  https://doi.org/10.1002/14651858.cd008165.pub3.PubMedGoogle Scholar
  39. 39.
    Walsh KA, O’Riordan D, Kearney PM, Timmons S, Byrne S. Improving the appropriateness of prescribing in older patients: a systematic review and meta-analysis of pharmacists’ interventions in secondary care. Age Ageing. 2016;45(2):201–9.  https://doi.org/10.1093/ageing/afv190.CrossRefPubMedGoogle Scholar
  40. 40.
    Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687.  https://doi.org/10.1136/bmj.g1687.CrossRefPubMedGoogle Scholar
  41. 41.
    Meulendijk MC, Spruit MR, Drenth-van Maanen AC, Numans ME, Brinkkemper S, Jansen PAF, et al. Computerized decision support improves medication review effectiveness: an experiment evaluating the STRIP assistant’s usability. Drugs Aging. 2015;32(6):495–503.  https://doi.org/10.1007/s40266-015-0270-0.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Kouladjian L, Gnjidic D, Chen TF, Hilmer SN. Development, validation and evaluation of an electronic pharmacological tool: the drug burden index calculator(c). Res Soc Adm Pharm. 2016;12(6):865–75.  https://doi.org/10.1016/j.sapharm.2015.11.002.CrossRefGoogle Scholar
  43. 43.
    Hoffmann TC, Oxman AD, Ioannidis JP, Moher D, Lasserson TJ, Tovey DI, et al. Enhancing the usability of systematic reviews by improving the consideration and description of interventions. BMJ. 2017;358:j2998.  https://doi.org/10.1136/bmj.j2998.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Aged CareRoyal North Shore HospitalSydneyAustralia
  2. 2.Northern Clinical School, Sydney Medical SchoolUniversity of SydneySydneyAustralia
  3. 3.Faculty of PharmacyUniversity of SydneySydneyAustralia
  4. 4.Pharmacy DepartmentRoyal North Shore HospitalSydneyAustralia
  5. 5.Kolling InstituteUniversity of Sydney and Royal North Shore HospitalSydneyAustralia

Personalised recommendations